Patient values in patient-provider communication about participation in early phase clinical cancer trials: a qualitative analysis before and after implementation of an online value clarification tool intervention

Autor: Liza G. G. van Lent, Mirte van der Ham, Maja J. A. de Jonge, Eelke H. Gort, Marjolein van Mil, Jeroen Hasselaar, Carin C. D. van der Rijt, Jelle van Gurp, Julia C. M. van Weert

Publikováno v: BMC Medical Informatics and Decision Making, Vol 24, Iss 1, Pp 1-16 (2024)

Abstract Background Patients with advanced cancer who no longer have standard treatment options available may decide to participate in early phase clinical trials (i.e. experimental treatments with uncertain outcomes). Shared decision-making (SDM) mo

Externí odkaz: https://doaj.org/article/6f31e3daebe4460897279e0a955a9984

Realizing better doctor-patient dialogue about choices in palliative care and early phase clinical trial participation: towards an online value clarification tool (OnVaCT)

Autor: Liza G. G. van Lent, Nicole K. Stoel, Julia C. M. van Weert, Jelle van Gurp, Maja J. A. de Jonge, Martijn P. Lolkema, Eelke H. Gort, Saskia M. Pulleman, Esther Oomen-de Hoop, Jeroen Hasselaar, Carin C. D. van der Rijt

Publikováno v: BMC Palliative Care, Vol 18, Iss 1, Pp 1-10 (2019)

Abstract Background Patients with advanced cancer for whom standard systemic treatment is no longer available may be offered participation in early phase clinical trials. In the decision making process, both medical-technical information and patient

Externí odkaz: https://doaj.org/article/5147c75b4ff6452697ab6a687669a1e3

Data from Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment

Autor: Emile E. Voest, Henk M.W. Verheul, Hans Gelderblom, Edwin Cuppen, Martijn P. Lolkema, Hans Morreau, Ann Hoeben, Mariette Labots, Carla M.L. van Herpen, Winette T.A. van der Graaf, Egbert F. Smit, Mathijs P. Hendriks, Laurens V. Beerepoot, Frans Erdkamp, Derk Jan de Groot, Emile D. Kerver, Jan Willem B. de Groot, Eelke H. Gort, Alwin D.R. Huitema, Vincent van der Noort, Erik van Werkhoven, Anne M.L. Jansen, Wendy J. de Leng, Paul Roepman, Joris van de Haar, Daphne L. van der Velden, Laurien J. Zeverijn, Hanneke van der Wijngaart, Jade M. van Berge Henegouwen, Louisa R. Hoes

Purpose:Patients with rare cancers (incidence less than 6 cases per 100,000 persons per year) commonly have less treatment opportunities and are understudied at the level of genomic targets. We hypothesized that patients with rare cancer benefit from

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20708b4724c2bca311186b13b326a529
https://doi.org/10.1158/1078-0432.c.6532484

Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment

Autor: Louisa R. Hoes, Jade M. van Berge Henegouwen, Hanneke van der Wijngaart, Laurien J. Zeverijn, Daphne L. van der Velden, Joris van de Haar, Paul Roepman, Wendy J. de Leng, Anne M.L. Jansen, Erik van Werkhoven, Vincent van der Noort, Alwin D.R. Huitema, Eelke H. Gort, Jan Willem B. de Groot, Emile D. Kerver, Derk Jan de Groot, Frans Erdkamp, Laurens V. Beerepoot, Mathijs P. Hendriks, Egbert F. Smit, Winette T.A. van der Graaf, Carla M.L. van Herpen, Mariette Labots, Ann Hoeben, Hans Morreau, Martijn P. Lolkema, Edwin Cuppen, Hans Gelderblom, Henk M.W. Verheul, Emile E. Voest

Publikováno v: Clinical Cancer Research, 28(7), 1402-1411. American Association for Cancer Research Inc.
Clinical Cancer Research, 28(7), 1402-1411. AMER ASSOC CANCER RESEARCH
Clinical Cancer Research, 28, 1402-1411
Hoes, L R, van Berge Henegouwen, J M, van der Wijngaart, H, Zeverijn, L J, van der Velden, D L, van de Haar, J, Roepman, P, de Leng, W J, Jansen, A M L, van Werkhoven, E, van der Noort, V, Huitema, A D R, Gort, E H, de Groot, J W B, Kerver, E D, de Groot, D J, Erdkamp, F, Beerepoot, L V, Hendriks, M P, Smit, E F, van der Graaf, W T A, van Herpen, C M L, Labots, M, Hoeben, A, Morreau, H, Lolkema, M P, Cuppen, E, Gelderblom, H, Verheul, H M W & Voest, E E 2022, ' Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment ', Clinical Cancer Research, vol. 28, no. 7, pp. 1402-1411 . https://doi.org/10.1158/1078-0432.CCR-21-3752
Clinical cancer research, 28(7), 1402-1411. American Association for Cancer Research Inc.
Clinical Cancer Research, 28, 7, pp. 1402-1411

Purpose: Patients with rare cancers (incidence less than 6 cases per 100,000 persons per year) commonly have less treatment opportunities and are understudied at the level of genomic targets. We hypothesized that patients with rare cancer benefit fro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d10b5fcc9b5bf485e35845851e46056d
https://doi.org/10.1158/1078-0432.ccr-21-3752

Conditional Inactivation of HIF-1 Using Intrabodies

Autor: Arjan J. Groot, Eelke H. Gort, Elsken van der Wall, Paul J. van Diest, Marc Vooijs

Publikováno v: Cellular Oncology, Vol 30, Iss 5, Pp 397-409 (2008)

Hypoxia is a hallmark of solid cancers and triggers the transcription of genes responsible for cell survival. The transcription factor Hypoxia-Inducible Factor 1 (HIF-1) is a key regulator in this response and frequently activated in human cancer. HI

Externí odkaz: https://doaj.org/article/5c6e3f22de65459b9fbe9a703b8de21e